Andere Sprachen I-Mab BOERSE MUENCHEN

Aktien

A2PVC6

US44975P1030

0VY

Realtime BOERSE MUENCHEN Andere Börsenplätze 21:44:03 27.06.2024			% 5 Tage	% 1. Jan.
1,58 ^EUR	-2,47 %		-2,41 %	-2,99 %

06.06.	I-Mab ernennt Phillip Dennis zum Chief Medical Officer	CI
05.06.	I-Mab arbeitet mit Bristol-Myers zusammen, um Givastomig in einer Kombinationsstudie für Magen- und Speiseröhrenkrebs zu untersuchen	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer	07.06.
I-Mab Appoints Phillip Dennis as Chief Medical Officer	06.06.
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	05.06.
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05.06.
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05.06.
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024	23.05.
I-Mab to Participate at the Jefferies Global Healthcare Conference	22.05.
I-MAB Filed 2023 Annual Report on Form 20-F	30.04.
Verastem Names John Hayslip as Chief Medical Officer	18.04.
I-Mab Announces Chief Medical Officer Changes	15.04.
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	08.04.
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	05.04.
I-Mab Completes Business Divestiture in China	02.04.
I-Mab Announces Closing of the Divestiture of Business Operations in China	02.04.
I-mab Biopharma Co., Ltd. completed the acquisition of I-Mab Biopharma Co., Ltd. from I-Mab.	02.04.
I Mab : Resignations of Director and Senior Management - Form 6-K	01.04.
I-Mab Announces Executive Resignation	01.04.
I-Mab Reports Earnings Results for the Full Year Ended December 31, 2023	14.03.
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	16.02.
I-Mab Divests China Operations, Shifts Focus to US Market	09.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen I-Mab BOERSE MUENCHEN

Aktien

A2PVC6

US44975P1030

0VY

Andere Sprachen

Filter